OnCore Biopharma was an American pharmaceutical company.
History
In January 2015, Tekmira Pharmaceuticals announced it would purchase OnCore in order to "focus on developing hepatitis B virus treatment by combining multiple therapeutic methods." OnCore would become a wholly-owned subsidiary, with ownership over Tekmira transferring in significant part to OnCore shareholders.[1] The merger was completed on March 4, 2015, with OnCore chairman Vivek Ramaswamy becoming chair of the new merged Tekmira.[2]
Personnel
| Name | Position | Notes |
|---|---|---|
| Patrick Higgins | Chief Executive Officer, Co-founder[3] | Pharmasset, SRx Consulting, Coley Pharmaceuticals, Viropharma, Roche, Schering |
| Michael McElhaugh | Chief Operating Officer, Co-founder | Bristol-Myers Squibb, Pharmasset, Viropharma, Merck, Thomas Jefferson University |
| Bryce Roberts | Chief Legal Officer, Head of Administration, Co-founder | Gilead Sciences, Pharmasset |
| Michael Sofia | Chief Scientific Officer, Head of R&D, Co-founder | Gilead Sciences, Pharmasset, Bristol-Myers Squibb, Transcell Technologies, Eli Lilly, Baruch S. Blumberg Institute |
| Vivek Ramaswamy | Chairman[1:1][2:1] | Roivant Sciences |
External links
Canada’s Tekmira to buy US-based OnCore Biopharma, focus on HBV treatment. (2015, January 12). Reuters. http://archive.today/2023.06.26-001352/https://www.reuters.com/article/oncore-ma-tekmira-idUSL3N0UR1EZ20150112 ↩︎ ↩︎
Rezler, J. P. (2015, March 4). Tekmira Announces Completion of the Merger With OnCore Creating a Leading Hepatitis B Solutions Company. Securities and Exchange Commission. https://web.archive.org/web/20230626001935/https://www.sec.gov/Archives/edgar/data/1447028/000117184315001290/newsrelease.htm ↩︎ ↩︎
Leadership Team. OnCore Biopharma. Retrieved September 13, 2014, from http://archive.today/2014.09.13-010442/http://www.oncorebiopharma.com/leadershipteam ↩︎
